A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active Controlled, Treat-Through study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn's Disease

Project: Other project

Project Details

StatusActive
Effective start/end date8/20/208/19/22

Funding

  • Eli Lilly: $8,250.00